As the CEO of Greyledge Technologies, I’ve had the privilege of watching our Company mature from a thought on a napkin to a unique and growing startup organization, amidst a challenging and dynamic field. I’m pleased to welcome so many exciting initiatives and great people involved in our development. I’ll be taking the helm of the blog to give Ted Sand a spell from his incredible work and insight that has helped so many clinicians navigate the Regenerative Medicine landscape over the years. As a segue to the post, I will be giving a talk at the upcoming meeting on regenerative medicine known as TOBI (The Orthobiologics Institute). I would like to give you some relevant background as well as a preview of my presentation.
Greyledge was formed more than seven years ago with the premise that physicians should accept a lack of knowledge about the composition of PRP and BMC preparations that were rapidly gaining favor in point-of-care (POC) regenerative medicine. After a couple of years of gaining experience with PRP and BMC treatment preparations in the clinic, I was able to review extensive hemoanalytical data gathered on the preparations. I presented a lecture at the 2012 TOBI meeting in which I summarized the compositional data recorded to-date. I also urged my colleagues to adopt hemoanalysis of their POC treatments in order to give themselves qualitative and quantitative control over the biologic products that we implant into patients.
In the intervening period, Greyledge has not only collected data on every biologic preparation that has been produced for patient treatment, but we have remained diligent in our efforts to refine the hemoanalytics platform, continually adapting it to meet the current needs of the field, including recent trends focused on leukocyte and RBC reduction of PRP as one example. I believe the regenerative community’s use of meticulous hemoanalytical analysis of PRP and BMC preparations will become even more valuable as the field continues to mature. The combination of knowing what is being injected and tracking that data with clinical outcomes measures gives the physician direct information to facilitate refinement of the practice of regenerative medicine. It also sets the stage to build data sets to drive product customization and optimization from a processing perspective in the future.
I’ll be giving a follow up to the original talk at the upcoming 2017 TOBI meeting in part to reiterate my previous challenge to the use of a hemoanalytic approach, but also to provide an update on my clinical experience over the intervening years involving thousands of biologics produced for treating patients. The talk is entitled: “Quantitative Analysis of PRP and BMC Samples: Experience in a Clinical Setting.” Not only will I provide an overview of my clinical use of quality controlled PRP and BMC, but I will introduce a new concept for organizing the hemoanalytic data that I anticipate will aid the community as it tries to optimize PRP and BMC compositions. The approach also should aid those physicians who actively track clinical outcomes as they look for trends in composition and frequency of treatment for a variety of orthopedic and musculoskeletal applications.
So often I hear colleagues preaching that we need to collect clinical outcomes data. While I applaud their enthusiasm, if we collect outcomes data with no knowledge of the composition of the preparations used in the treatment, we essentially are driving blind down a road where harsh and critical eyes are evaluating our approach to quality control, and who remain ready to pounce on the community’s lack of attention to the sound scientific and clinical practice of knowing what is going into the patient.
One of my jobs at Greyledge is to ensure that our organization is fulfilling its foundational mission and purpose: “To leverage scientific advancements in creating autologous biologic preparations, which enable physicians to optimize the practice of regenerative medicine.” And as a testament to that commitment, there are a number of clinical and scientific activities underway at Greyledge that I believe will make the use of hemoanalytic data and other analyses of PRP and BMC more important than ever.
I am looking forward to providing the update at TOBI in order to again advance the position that collecting validated hemoanalytic data is vital as the community addresses multiple challenges facing the field of regenerative medicine.
David Karli, MD, MBA (Founder and CEO of Greyledge Technologies)